Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:approves |
gptkb:2013
gptkb:FDA |
| gptkbp:can_be_combined_with |
gptkb:trastuzumab
chemotherapy |
| gptkbp:chemical_formula |
C2026 H2500 N442 O508 S16
|
| gptkbp:clinical_trial |
gptkb:TH3_RESA_trial
gptkb:EMILIA_trial gptkb:KATHERINE_trial gptkb:MARIANNE_trial Phase III |
| gptkbp:clinical_use |
after prior treatment with trastuzumab and a taxane
|
| gptkbp:contraindication |
hypersensitivity to components
severe hepatic impairment |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:formulation |
lyophilized powder for reconstitution
|
| https://www.w3.org/2000/01/rdf-schema#label |
ado-trastuzumab emtansine
|
| gptkbp:indication |
metastatic breast cancer
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count |
| gptkbp:marketed_as |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
delivers cytotoxic agent to cancer cells
|
| gptkbp:patient_population |
adult women
HER2-positive patients |
| gptkbp:pharmacokinetics |
half-life of approximately 4 days
|
| gptkbp:rounds |
biliary
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:service_frequency |
every 3 weeks
|
| gptkbp:side_effect |
gptkb:anemia
dizziness fatigue headache nausea hypertension fever vomiting diarrhea rash insomnia constipation dry mouth chills peripheral neuropathy thrombosis thrombocytopenia hypotension alopecia hepatotoxicity infusion reactions neutropenia cardiotoxicity musculoskeletal pain |
| gptkbp:storage |
2 to 8 ° C
|
| gptkbp:targets |
HER2 protein
|
| gptkbp:trade |
gptkb:Kadcyla
|
| gptkbp:used_for |
treatment of HER2-positive breast cancer
|
| gptkbp:weight |
approximately 1000 k Da
|
| gptkbp:bfsParent |
gptkb:HER2-positive_breast_cancer
|
| gptkbp:bfsLayer |
6
|